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Purpose: Exfoliation syndrome (XFS) is characterized by an accumulation of abnormal extracellular material in the
anterior part of the eye that frequently leads to increased intraocular pressure and glaucomatous optic neuropathy. Recently,
two non-synonymous polymorphisms (rs1048661 G>T and rs3825942 G>A) of lysyl oxidase-like protein 1 (LOXL1), a
monoamine oxidase that catalyzes the polymerization of tropoelastin to elastin, were found to be associated with increased
risk for XFS and exfoliation glaucoma (XFG). The aim of the present study was to investigate the role of these LOXL1
variants in a Central European cohort of Caucasian patients with XFG.
Methods: The present case-control study comprised of 167 unrelated patients with XFG and 170 control subjects.
Genotyping of the LOXL1 rs1048661 and rs3825942 polymorphisms was done using polymerase chain reaction.
Results: The frequency of allele G of rs1048661 as well as rs3825942 was significantly higher in patients than in controls
(rs1048661: 0.841 in patients versus 0.669; p<0.001; rs3825942: 0.994 in patients versus 0.817; p<0.001). Odds ratios of
52.1 (95% confidence interval [CI]: 13.85–195.6) and 14.67 (95% CI: 3.81–56.2), respectively, were calculated for the
two high-risk haplotypes GG and TG compared to the haplotype GA.
Conclusions: Our data confirm the previously reported association between LOXL1 polymorphisms and XFG and extend
our knowledge to a Central European population.
Exfoliation  syndrome  (XFS;  OMIM  177650)  is
characterized by an accumulation of abnormal extracellular
fibrillar material not only in different structures of the eye but
also in various extraocular tissues [1]. Therefore, XFS has
been  suggested  to  be  a  generalized  elastic  fibrillopathy.
Exfoliation fibrils are highly characteristic and consist of a
protein core including components of basement membrane
and the elastic fiber system surrounded by glycoconjugates
[2].  Prevalence  of  XFS  varies  widely  with  the  highest
prevalence in the Nordic European countries (up to 25%) and
5%–15% in Central European populations [2,3].
Clinically, exfoliation material is recognized as a whitish
material on the anterior capsule of the lens and flakes at the
pupillary border. Secondary open-angle glaucoma due to XFS
(exfoliation glaucoma, XFG) develops as a consequence of
deposition of exfoliation material and of liberated iris pigment
in the trabecular meshwork leading to elevated intraocular
pressure and consecutively glaucomatous optic neuropathy
[4].
The exact cause for the production of the exfoliation
material  is  still  elusive,  but  there  is  ample  evidence  that
genetic factors may contribute to the pathogenesis of XFS.
Various family-based studies reported a higher frequency of
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XFS among relatives of patients with XFS [5-8]. Furthermore,
increased rates of loss of heterozygosity have been found in
specimens of the anterior segment in individuals with XFS,
suggesting genetic factors play a role in the pathogenesis of
the disease [9].
Most  importantly,  a  recent  genome-wide  association
study from Icelandic and Swedish patients with XFS and XFG
found  two  common  non-synonymous  single  nucleotide
polymorphisms in exon 1 of the lysyl oxidase-like protein 1
gene (LOXL1; OMIM 153456) conferring increased risk for
the  development  of  XFS  and  XFG  (rs1048661  and
rs3825942) [10]. rs 1048661 induces an amino acid change
from arginine to leucine at position 141 (R141L) whereas
rs3825942 induces an amino acid change from glycine to
asparagine at position 153 (G153D).
So far, the potential role of these polymorphisms has not
yet  been  determined  in  a  Central  European  population.
Therefore, our study was set to investigate the aforementioned
LOXL1 variants in a Central European cohort of Caucasian
origin.
METHODS
One hundred sixty-seven unrelated patients with XFG and 170
control subjects were enrolled in the present retrospective
case-control study. All study participants were Caucasians
from  the  same  geographical  area  in  the  southern  part  of
Austria.  Participants  were  seen  at  the  Department  of
Ophthalmology, Medical University of Graz, Graz, Austria
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857between May 2003 and April 2007 and gave informed, written
consent  before  enrollment.  The  study  was  conducted  in
accordance with the National Gene Technology Act of Austria
and the guidelines of the local ethics committee.
Patients with XFG underwent slit lamp biomicroscopy in
mydriasis, testing for best corrected visual acuity, Goldmann
applanation  tonometry,  gonioscopy,  pachymetry,  and
standard automated perimetry (Octopus 101, programme G2;
Interzeag, Bern, Switzerland) or – in cases of profoundly
decreased  visual  acuity  –  Goldmann  perimetry.  Control
subjects  underwent  slit  lamp  biomicroscopy  in  mydriasis,
Goldmann  applanation  tonometry,  and  testing  for  best
corrected visual acuity. Optic discs in all participants were
assessed by glaucoma specialists (C.F. and G.M.).
XFG was defined by the presence of typical exfoliation
material on the anterior lens capsule, an intraocular pressure
of at least 22 mmHg before initiation of a pressure-lowering
therapy, an open anterior chamber angle, optic disc changes
characteristic  for  glaucoma  (notching,  thinning  of  the
neuroretinal rim, and increased cup/disc ratio in relation to the
optic  disc  size),  visual  field  defects  characteristic  for
glaucoma (inferior or superior arcuate scotoma, nasal step,
and  paracentral  scotoma),  and  the  absence  of  conditions
leading to secondary glaucoma.
Control subjects showed biomicroscopically no evidence
of exfoliation material on the anterior capsule of the lens and
no morphological damage indicative for open-angle or angle
closure  glaucoma.  Control  subjects  were  admitted  to  our
department for cataract surgery.
Genotype determination: Genomic DNA was extracted
from peripheral blood lymphocytes by standard techniques
and  stored  at  –70  °C  until  genotype  determination.  For
genotyping of the LOXL1 R141L polymorphism, a 179 base-
pair segment containing the polymorphic site was amplified
by polymerase chain reaction using forward primer 5′-GCC
GTC GGG GAC AGC A-3′ and reverse primer 5′-TAG TTC
TCG TAC TGG CTG ACG AA-3′. Amplified products were
digested with restriction enzyme SmaI (New England Biolabs,
Frankfurt,  Germany).  The  141R  allele  was  cut  into  two
fragments of 151 and 28 base pairs whereas the 141L allele
remained uncut. Fragments were separated on 2.5% agarose
gels and visualized by use of ethidium bromide.
The LOXL1 G153D polymorphism was determined by a
5′-exonuclease assay (TaqMan; Applied Biosystems, Vienna,
Austria) using forward primer 5′-ACC TCC GTC TCC CAG
CAA-3′,  reverse  primer  5′-TGC  TGG  CGA  AGG  CCG
AAG-3′, LOXL1–153G-probe VIC-CGG AGC CCC CGT G-
NFQ, and LOXL1–153D-probe FAM-AGG CGG AGT CCC
CGT-NFQ (Applied Biosystems, Vienna, Austria). The assay
was performed according to the manufacturer’s instructions,
and end-point fluorescence was measured in a lambda Fluoro
320  plus  plate  reader  (MWG  Biotech  AG,  Ebersberg,
Germany) using excitation/emission filters of 485/530 nm and
530/572 nm, respectively. The data were exported into Excel
format and depicted and analyzed as a scatter plot.
Statistical analysis: Descriptive statistics were used to
calculate frequencies and percentages of discrete variables.
Continuous data are given as mean±standard deviation (SD).
Means  were  compared  using  the  Mann–Whitney  test.
Proportions of groups were compared by the χ2 test. Odds ratio
(OR) and 95% confidence interval (95% CI) were calculated
by logistic regression. The criterion for statistical significance
was  p≤0.05.  The  Hardy–Weinberg  (HW)  equilibrium  has
been calculated using HW Diagnostics-Version 1.beta (Fox
Chase Cancer Center, Philadelphia, PA). Statistical analysis
was done using the SPSS statistical package (SPSS v14.0,
Chicago,  Illinois)  and  haplotype  analysis  was  done  using
Haploview 4.0 [11].
RESULTS
The  present  study  comprised  167  patients  with  XFG  (91
female, 76 male) and 170 control subjects (95 female, 75
male). The mean age of patients with XFG was 75.7 years
(range 50.3–91.6 years), and the mean age of control subjects
was 77.1 years (range 58.9–92.7 years). Patients with XFG
had a mean deviation of 13.0±6.9 decibel (dB), a mean loss
of variance of 36.7±21.5 dB2, a mean intraocular pressure of
26.0±11.2 mmHg, and a mean cup disc ratio of 0.80±0.16 in
the worse eye.
The success rate of genotyping was 93.5% for rs1048661
and  94.1%  for  rs3825942.  The  observed  genotype
distributions  did  not  deviate  from  those  predicted  by  the
Hardy–Weinberg equilibrium. Table 1 shows the genotype
and allele frequencies of rs1048661 and rs3825942 in patients
with XFG and control subjects. In both polymorphisms, the
prevalence of the GG genotype as well as the frequency of
allele G was significantly higher in patients with XFG than in
control subjects. An odds ratio of 2.69 (95% CI: 1.59–4.54)
was calculated for allele G of rs1048661. For allele G of
rs3825942, an odds ratio of 37.29 (95% CI: 6.35–218.02) was
calculated.
The two variants are in strong linkage disequilibrium
(D’=1.0), and only three possible haplotypes were observed
in our cohort (Table 2). Compared to the protective haplotype
GA, the GG haplotype conferred an odds ratio of 52.1 (95%
CI: 13.85–195.6) while the TG haplotype conferred an odds
ratio of 14.67 (95% CI: 3.81–56.2).
Positive likelihood ratio and negative likelihood ratio
were 1.26 and 0.47, respectively, for allele G of rs1048661.
For  allele  G  of  rs3825942,  positive  likelihood  ratio  and
negative likelihood ratio were 1.22 and 0.03, respectively.
DISCUSSION
Mainstay of the pathogenesis of exfoliation syndrome is the
accumulation  of  pathognomonic  fibrils  in  the  anterior
segment of the eye as well as in extraocular locations [1].
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858These fibrils are partly composed of components of the elastic
fiber system like elastin, tropoelastin, amyloid P, and latent
TGF-β  binding  proteins  [2,4].  As  a  monoamine  oxidase
secreted  by  fibrogenic  cells,  LOXL1  catalyzes  the
deamination of lysyl residues of tropoelastin, the monomeric
form of elastin. This deamination leads to the polymerization
of  tropoelastin  to  elastin,  which  is  the  first  step  of
elastogenesis [12,13]. Therefore, it is biologically plausible
that  an  altered  function  of  one  of  the  key  enzymes  of
elastogenesis leads to an increased susceptibility for XFS and
XFG.  Mice  lacking  LOXL1  display  tropoelastin
accumulation in multiple tissues, which leads to pelvic organ
prolapse,  emphysematous  changes,  and  vascular
abnormalities  [13].  Interestingly,  regarding  primary  open-
angle glaucoma, elastin and lysyl oxidase-like protein 2 has
been suggested as candidate susceptibility genes [14].
The present study being the first in a Central European
population confirms the strong association between LOXL1
variants and XFG. Beside the original study from Thorleifsson
and coworkers [10] that included an Icelandic and a Swedish
cohort, four studies from the United States, one study from
Australia,  one  study  from  Japan,  and  one  from  India
investigating LOXL1 polymorphisms in XFS and XFG have
been performed [10,15-21]. The prevalence of allele G of
rs1048661 and rs3825942 found in the present study were
remarkably similar to four of these studies [14-16] while in
three studies, slightly lower prevalences have been reported
(Table 3) [18-20]. This fact may be due to greater ethnic
heterogeneity  of  the  investigated  populations  or  different
additional  genetic  or  environmental  risk  factors.  It  is
noteworthy  that  in  the  study  from  Japan,  no  allele  G  in
rs1048661 was detected in patients with XFG while frequency
of allele G in rs3825942 was found to be 100% in their study
[21].  In  contrast,  in  patients  with  XFG  in  our  cohort
frequencies of the G alleles of rs1048661 and rs3825942 was
84.1% and 99.4%, respectively, pointing towards significant
differences in the prevalence of rs1048661 among different
ethnicities.
With positive and negative likelihood ratios of 1.26 and
0.47 (allele G of rs1048661) and 1.22 and 0.03 (allele G of
rs3825942),  respectively,  genetic  testing  for  XFG  based
solely  on  these  polymorphisms  of  LOXL1  can  not  be
recommended.
TABLE 1. GENOTYPE AND ALLELE FREQUENCIES OF RS1048661 AND RS3825942 IN PATIENTS WITH EXFOLIATION GLAUCOMA AND
CONTROL SUBJECTS.
SNP Patients with XFG (n=167) Control subjects (n=170) p-value
rs1048661
GG
119 (71.3%) 79 (46.5%) 5.1x10
−6
GT 43 (25.7%) 70 (41.2%)
TT 5 (3.0%) 21 (12.4%)
rs1048661
allele G
0.841    0.671 2.55x10
−7
rs3825942
GG
165 (98.8%) 109 (64.1%) 9.91x10
−19
GA 2 (1.2%) 60 (35.3%)
AA - 1 (0.6%)
rs3825942
allele G
0.994 0.817 5.76x10
−15
Genotype and allele frequencies of rs1048661 and rs3825942 in exon 1 of LOXL1 in Central European patients with exfoliation
glaucoma versus Central European control subjects. Proportions of groups were compared by the χ2 test. Numbers for genotypes
are n (%).
TABLE 2. FREQUENCIES OF LOXL1 HAPLOTYPES IN PATIENTS WITH EXFOLIATION GLAUCOMA AND CONTROL SUBJECTS.
Haplotype Patients with XFG (n=167) Control subjects (n=170) p-value
G G 279 (83.5%) 166 (48.8%) 1.86x10−21
T G 53 (15.9%) 112 (32.9%)
G A 2 (0.06%) 62 (18.2%)
Frequencies of haplotypes of rs1048661 and rs3825942 in exon 1 of LOXL1 in Central European patients with exfoliation
glaucoma versus Central European control subjects. Haplotype analysis was performed using Haploview 4.0. Proportions of
groups were compared by the χ2 test. Numbers for haplotypes are n (%).
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859In conclusion, the results of our study demonstrate the
importance  of  the  LOXL1  polymorphisms  in  a  Central
European population of Caucasian origin. As other genetic or
environmental  factors  are  likely  to  be  involved  in  the
pathogenesis of XFG, further studies are warranted.
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